Neurocrine Biosciences Inc vs Solaredge Technologies Inc — how do they compare? Neurocrine Biosciences Inc trades at $156.74 (market cap $16.46B), while Solaredge Technologies Inc trades at $32.29 (market cap $2.05B). The key difference: Neurocrine Biosciences Inc is far larger — about 8× Solaredge Technologies Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SEDG | |
|---|---|---|
Market Cap | $16.46B | $2.05B |
Sector | Health | Technology |
52-Week High | $185.50 | $78.51 |
52-Week Low | $123.10 | $25.10 |
Enterprise Value | $16.48B | $1.91B |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.
SolarEdge Technologies (SEDG) trades at $32.34, up 0.4% on the day, amid a challenging period marked by negative profitability and a bearish technical signal. Recent Q2 2026 earnings beat expectations with a surprise profit, but weak Q3 guidance and a net loss under GAAP accounting highlight ongoing struggles. The stock faces headwinds from soft U.S. residential demand and policy dependency, while European growth offers some offset. Analyst sentiment is mixed, with a consensus price target of $35.15 but a majority hold rating reflecting execution risks.
The outlook remains cautious due to persistent losses, high debt, and volatile cash flows. Investment opportunity hinges on margin recovery and policy support, but risks include competitive pressures, liquidity concerns, and macroeconomic sensitivity. Near-term performance will depend on Q3 results and U.S. market trends.
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →